Aprepitant for erlotinib-induced pruritus.
Vincenzi
Bruno
B
Tonini
Giuseppe
G
Santini
Daniele
D
D000328:Adult; D000368:Aged; D000077608:Aprepitant; D000069347:Erlotinib Hydrochloride; D005260:Female; D006801:Humans; D008297:Male; D009025:Morpholines / Q000627:therapeutic use*; D064729:Neurokinin-1 Receptor Antagonists; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011537:Pruritus / Q000139:chemically induced / Q000188:drug therapy*; D011799:Quinazolines / Q000009:adverse effects*
D009025:Morpholines; D064729:Neurokinin-1 Receptor Antagonists; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000077608:Aprepitant; D000069347:Erlotinib Hydrochloride